



**СРПСКИ АРХИВ**  
ЗА ЦЕЛОКУПНО ЛЕКАРСТВО  
**SERBIAN ARCHIVES**  
OF MEDICINE

Address: 1 Kraljice Natalije Street, Belgrade 11000, Serbia

+381 11 4092 776, Fax: +381 11 3348 653

E-mail: [office@srpskiarhiv.rs](mailto:office@srpskiarhiv.rs), Web address: [www.srpskiarhiv.rs](http://www.srpskiarhiv.rs)

**Paper Accepted\***

**ISSN Online 2406-0895**

**Original Article / Оригинални рад**

Mioljub Ristić<sup>1,2,†</sup>, Vesna D. Stojanović<sup>1,3</sup>, Vladimir Petrović<sup>1,2</sup>, Ulrich Heininger<sup>4</sup>

**Evaluation of the diagnostic utility of the new clinical case definition  
of pertussis – experience from sentinel and hospital-based  
pertussis surveillance**

Евалуација дијагностичке вредности нове дефиниције случаја великог  
кашља – искуства из сентинелног и хоспиталног  
надзора над пертусисом

<sup>1</sup>University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia;

<sup>2</sup>Institute of Public Health of Vojvodina, Novi Sad, Serbia;

<sup>3</sup>Institute for Child and Youth Health Care of Vojvodina, Novi Sad, Serbia;

<sup>4</sup>University of Basel Children's Hospital (UKBB), Basel, Switzerland

**Received: April 13, 2018**

**Revised: January 21, 2019**

**Accepted: February 22, 2019**

**Online First: March 20, 2019**

**DOI: <https://doi.org/10.2298/SARH180413022R>**

\* **Accepted papers** are articles in press that have gone through due peer review process and have been accepted for publication by the Editorial Board of the *Serbian Archives of Medicine*. They have not yet been copy edited and/or formatted in the publication house style, and the text may be changed before the final publication.

Although accepted papers do not yet have all the accompanying bibliographic details available, they can already be cited using the year of online publication and the DOI, as follows: the author's last name and initial of the first name, article title, journal title, online first publication month and year, and the DOI; e.g.: Petrović P, Jovanović J. The title of the article. *Srp Arh Celok Lek*. Online First, February 2017.

When the final article is assigned to volumes/issues of the journal, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the journal. The date the article was made available online first will be carried over.

**†Correspondence to:**

Mioljub RISTIĆ

Institute of Public Health of Vojvodina, Futoška 121, 21000 Novi Sad, Serbia

E-mail: [mioljub.ristic@mf.uns.ac.rs](mailto:mioljub.ristic@mf.uns.ac.rs)

## Evaluation of the diagnostic utility of the new clinical case definition of pertussis – experience from sentinel and hospital-based pertussis surveillance

Евалуација дијагностичке вредности нове дефиниције случаја великог кашља – искуства из сентинелног и хоспиталног надзора над пертусисом

### SUMMARY

#### Introduction/Objective

Global surveillance systems use different clinical case definitions of pertussis.

The aim of this study was to identify sign and symptom combinations with best relation with laboratory-confirmed pertussis.

**Methods** A one-year prospective observational study to evaluate the performance of the clinical case definition of pertussis proposed by the Global Pertussis Initiative (GPI) for three age groups (0–3 months, four months–9 years and  $\geq 10$  years) was performed in Novi Sad. Laboratory confirmation of *B. pertussis* infection was obtained using the DNA polymerase chain reaction (PCR) or ELISA serology tests.

**Results** From October 1, 2013 to September 30, 2014, 103 (32.3%) of 319 participants with suspected pertussis had laboratory-confirmed pertussis. Combined whooping, post-tussive emesis, and worsening of symptoms at night was the best predictor of pertussis in out-patients aged 4 months–9 years (positive likelihood ratio LR+, 11.6), while among in-patients of the same age group it was apnoea (LR+ 13.5). The LR+ in out-patients aged  $\geq 10$  years for combinations of apnoea + post-tussive emesis or combination of whoop + sweating episodes between paroxysms + post-tussive emesis was 16.8, while among in-patients LR+ was  $< 2.3$  for all combinations in the same age group.

**Conclusions** The GPI case definitions for pertussis are good predictors for laboratory-confirmed pertussis and are useful for the purpose of pertussis surveillance.

**Keywords:** pertussis (whooping cough); Global Pertussis Initiative; case definition; surveillance

### САЖЕТАК

**Увод/Циљ** У надзору над пертусисом у свету се користе различите дефиниције случаја великог кашља.

Циљ рада био је да се одреде оне комбинације знакова и симптома који доприносе најбољем препознавању великог кашља.

**Методе рада** У циљу евалуације знакова и симптома из дефиниција случаја великог кашља предложених од стране Глобалне пертусисне иницијативе (ГПИ) за три узрасне групе (0–3 месеца, четири месеца–9 година и узраст од 10 година и старијих), у Новом Саду је спроведена проспективна опсервациона студија у трајању од једне године. Лабораторијска потврда инфекције изазване бактеријом *B. pertussis* је добијена употребом PCR метода или серолошким (ELISA) тестовима.

**Резултати** У периоду од 1. октобра 2013. године до 30. септембра 2014. године, од укупно 319 испитаника са сумњом на велики кашаљ, код 103 (32,3%) пацијента је добијена лабораторијска потврда великог кашља. Комбинација инспираторног стридора, повраћања након кашља и погоршања симптома током ноћи је имала највећи дијагностички значај (степен вероватноће позитивног резултата (LR+) 11,6), у доказивању пертусиса у сентинелном надзору међу пацијентима узраста од 4 месеца до 9 година, док је међу хоспитализованима истог узраста најбољи предиктор позитивног резултата била апнеа (LR+ 13,5). У узрасту 10 година и старијих, LR+ за пацијенте регистроване у сентинелном надзору са присутном апнеом удруженом са повраћањем након кашља или са комбинацијом инспираторног стридора удруженог са презнојавањем између пароксизама и повраћењем након кашља је била 16,8, док је међу хоспитализованим пацијентима овог узраста LR+ био мањи од 2,3 за све комбинације знакова/симптома.

**Закључак** Дефиниције случаја ГПИ имају добар дијагностички значај у циљу откривања оболевања од великог кашља и зато могу бити корисне у надзору над овом болешћу.

**Кључне речи:** велики кашаљ (пертусис); Глобална пертусисна иницијатива; дефиниција случаја; надзор

## INTRODUCTION

Pertussis remains an important cause of morbidity and mortality among infants and children, even in countries with high vaccination coverage rates. The World Health Organization (WHO) estimates that 50 million cases and 300,000 deaths occur every year because of pertussis, and case-fatality rates of pertussis in developing countries are estimated to be as high as 4% in infants [1]. Consequently, establishing a reliable diagnosis of pertussis has become increasingly important [2, 3].

Because of the heterogeneity in clinical manifestations of pertussis, lack of general availability of laboratory confirmation of disease, mixed infections, and a low index of suspicion among many physicians, pertussis is under-recognized worldwide. In addition, the absence of a sensitive clinical case definition of pertussis has contributed to missed or misdiagnosed pertussis cases [4, 5, 6].

Existing clinical case definitions of pertussis are based on clinical presentation in infants and children, but they are also used for adolescents and adults who may manifest distinct signs and symptoms. Therefore, in an effort to improve the diagnosis of pertussis, the Global Pertussis Initiative (GPI) proposed an algorithm based on the most common signs and symptoms of pertussis for three age groups, i.e. 0–3 months, four months–nine years, and  $\geq 10$  years old [7].

The epidemiology of pertussis in Novi Sad has not been well-described until 2012 when an improved surveillance method for pertussis was introduced following the recommendations of GPI [7]. We then determined that pertussis was widespread in our population affecting patients at any age [8, 9].

The aim of the present study was to determine the most predictive signs and symptoms of pertussis and to evaluate the diagnostic performance of certain combinations of signs and symptoms based on the case definitions of pertussis proposed by the GPI.

## METHODS

### Study design, specimen collection and laboratory testing

The recruitment period was from October 1, 2013 to September 30, 2014 (52 weeks). According to the GPI [7], methods have been described in detail before [9]. Briefly, we simultaneously conducted prospective surveillance at both primary (out-patients) and tertiary (in-patients) health care levels in the city of Novi Sad. Participants were identified and sampled by the physicians in the two health care levels as a part of their daily routine. Hospital surveillance for the whole territory of the city of Novi Sad (341,624 inhabitants) was conducted in two in-patient facilities: pulmonology clinic of Institute of Child and Youth Health Care of Vojvodina (paediatric in-patient facility) and Institute of Pulmonary Diseases of Vojvodina (adult in-patient facility). We included only patients who fulfilled one or more criteria of clinical case definitions for the age groups (0–3 months, four months–nine years, and  $\geq 10$  years old) [7].

Patient data collection, sampling and transport of patient material as well as the laboratory testing of samples and interpretation of results was performed according to the previously used methodology [7, 9].

We classified participants as “fully vaccinated” according to their age, “partly vaccinated” (cases who had received  $\geq 1$  but not all the vaccinations required for their age), and “unvaccinated”. Due to waning immunity after vaccination against pertussis, only vaccination status for participants  $< 18$  years was recorded. All participants aged  $\geq 18$  were considered as participants with an unknown vaccination status.

Verbal informed consent was obtained from patients before swab taking in accordance with national regulations and written consent from parents or guardians was obtained.

### Statistical analysis

Because we registered only five laboratory-confirmed pertussis cases in infants aged 0–3 months, we did not perform a validation of certain symptoms in this age group. A two-tailed P value  $p < 0.05$  was considered to indicate statistical significance for all statistical tests.

Data analysis was performed using the SPSS version 22 software and MedCalc for Windows, version 12.3.0 (MedCalc Software, Mariakerke, Belgium).

## RESULTS

During the study period, a total of 319 participants with suspected pertussis were enrolled, and 103 (32.3%) had laboratory-confirmed pertussis by PCR or serology. Among the laboratory-confirmed cases, 29, 71 and 3 patients were positive by PCR, ELISA and both tests, respectively. *B. parapertussis* or *B. bronchiseptica* infections were not detected. No participant with suspected pertussis had been vaccinated against pertussis during the 12 months before inclusion into the study, and there were no deaths. Patients with laboratory-confirmed pertussis were younger than those without laboratory confirmation ( $p = 0.030$ ), and the proportion of pertussis was higher among hospitalized patients compared to outpatients ( $p < 0.001$ ), and higher among “unvaccinated” and “partly vaccinated” children compared to those where “fully vaccinated”, although the difference was not significant (OR 1.87, 95% CI 0.97–3.60,  $p = 0.062$ ) (data not shown).

Pertussis was confirmed in 31.3% (5/16), 27.4% (34/124) and 35.8% (64/179) in individuals 0–3 months, four months–9 years, and  $\geq 10$  years old, respectively.

In infants 0–3 months of age, the mandatory signs and symptoms (MSS) in combination with pneumonia (OR 6.75, 95% CI 0.64–71.18) and close exposure to a person with a prolonged afebrile cough illness (contact) (OR 2.50, CI 0.12–50.45) had a strong association with pertussis, but due to a limited number of participants, differences between positive and negative cases were not statistically significant ( $p > 0.05$ )

In the four months–9 years and  $\geq 10$  years age groups, the MSS accompanied by whoop or apnoea or post-tussive emesis or worsening of the symptoms at night were significantly associated with having a laboratory-confirmed pertussis ( $p < 0.05$ ). Among the participants aged four months–9 years, only combination of MSS and pneumonia was not associated with pertussis, and in the  $\geq 10$  years age group, only MSS accompanied by sweating episodes between paroxysms was not a predictor of laboratory-confirmed pertussis ( $p > 0.05$ ) (Table 1).

The diagnostic performance of the selected sign and symptom combinations for pertussis in the participants aged four months-9 years is shown in Table 2 and for those  $\geq 10$  years in Table 3.

Among the out-patients, the MSS of pertussis in the four months-9 years age group accompanied by whoop, post-tussive emesis and worsening symptoms at night had the highest diagnostic value of laboratory-confirmed pertussis (LR+ 11.6, 95% CI 2.6–51.8), while a combination of the MSS and apnoea was the strongest predictor of pertussis among the in-patients (LR+ 13.5, 95% CI 1.8–99.6). When stratified by the surveillance sites, the MSS along with apnoea was significantly more sensitive in the hospital than in the sentinel sites (42.1% vs. 6.7%,  $p = 0.022$ ). The MSS in combination with post-tussive emesis or accompanied by post-tussive emesis and contact were significantly more specific among the out-patients than in the in-patients (77.6% vs. 43.8%,  $p = 0.001$  and 100.0% vs. 90.6%,  $p = 0.018$ , respectively).

According to the values of LR+ for participants aged  $\geq 10$  years, among the in-patients there was no combination with LR+ greater than 2.3. In the out-patients, including the MSS in combination with one or more signs and symptoms through sentinel surveillance, we have determined that five different combinations from the proposed case definition were the strongest predictors of pertussis in the  $\geq 10$  years age group (LR+ above 10).

Compared to the values of sensitivities and specificities among the participants aged  $\geq 10$  years in the two surveillance systems, including the MSS of pertussis, post-tussive emesis was significantly more sensitive among the out-patients than in the in-patients (61.3% vs. 27.3%,  $p = 0.007$ , respectively). The combination of MSS along with worsening of symptoms at night was significantly more sensitive (84.9% vs. 61.3%,  $p = 0.034$ , respectively), and the combination of MSS accompanied by whoop and post-tussive emesis was significantly less specific (81.8% vs. 97.1%,  $p = 0.019$ , respectively) in hospitalized than in out-patient cases.

## DISCUSSION

The main aim of the study was to validate the pertussis case definitions of the GPI. A very important aspect of our study was the estimation of the sensitivity and specificity of

various combinations of signs and symptoms of the clinical case definitions proposed by the GPI.

One of the first published studies, in which certain signs and symptoms of pertussis case definition were evaluated, was conducted during two community outbreak years in Wisconsin and Delaware (in 1985 and 1986) [10]. In this study, participants were enrolled in the outbreak settings with wide inclusion criteria (one or more symptoms of acute respiratory illness, regardless of the age of participants), and a total of 50% of patients had laboratory evidence of pertussis, while the prevalence of laboratory-confirmed pertussis in our study was 32.3%. Except for the pertussis outbreak in the families, there were no registered outbreaks in the population in the city of Novi Sad during our study period [8, 9]. Due to the fact that participants in our study were enrolled during an epidemic free year and because we included only those who fulfilled the required signs and symptoms for three age groups, we are convinced that mentioned differences would have contributed to the discrepancy of the results in the cited study [10].

Surveillance of pertussis in many countries across the world is based on the clinical case definitions of pertussis recommended by the WHO, the US Centers for Disease Control Prevention (CDC) or the European Centre for Disease Prevention and Control (ECDC). Unlike these commonly applied case definitions, which include a cough duration of two weeks or longer for all age groups, in the clinical case definitions of pertussis proposed by the GPI, cough duration depends on the age of the patients [7]. Thus, we included all patients aged  $\geq 10$  years, who had a non-productive, paroxysmal cough of  $\geq 2$  weeks duration without fever. Among the participants younger than 10 years, MSS were paroxysmal cough with no or minimal fever (patients aged 4 months-9 years), and cough and coryza with no or minimal fever (patients 0–3 months of age), regardless of the duration of cough. The differences between case definitions did not allow us to compare our results with the published studies by other investigators. Certain clinical criteria of the GPI case definitions helped us to detect pertussis more efficiently in patients younger than 10 years old, in whom coughing duration was  $< 2$  weeks.

The primary objective of our study was to estimate the highest values both of sensitivity and specificity, complimented by PPV and LR+ for certain sign and symptom combinations from the case definitions proposed by the GPI.

We provided evidence that whoop in combination with prerequisite signs and symptoms had the highest sensitivity of pertussis in the four months-9 years age group who have visited the primary or tertiary health care levels (73% vs. 63%, respectively). Nonetheless, among the in-patients, post-tussive emesis had the same sensitivity as a whoop. Among the out-patients, seven different sign and symptom combinations had specificities of 95% or more, while in the in-patients four different combinations had specificities above 96%.

As is known, the significance of a high PPV is helpful for clinical case management to maximize the detection of laboratory-confirmed cases among the tested participants [11]. We found that the out-patients aged four months-9 years with a combination of different symptoms which obligatory included MSS, whoop and contact had a high number of true positive pertussis cases (PPV >71%), while the in-patients had a highest PPV for apnoea in combination with MSS (89%) and for MSS combined with whoop, post-tussive emesis, worsening of the symptoms at night and contact (PPV = 100%).

For the participants aged  $\geq 10$  years, MSS combined with whoop had the highest sensitivity and a moderate PPV (71% and 45%, respectively) in the out-patients, whereas the MSS in combination with worsening of symptoms at night had the highest sensitivity and high PPV (85% and 80%, respectively) among in-patients. Apnoea in combination with MSS or in combination with other signs and symptoms had the highest specificity among the in-patients and out-patients and was exceeding the value of 97% in all observed combinations.

After examining the performance of the WHO pertussis case definition (cough  $\geq 14$  days with either paroxysmal cough, inspiratory whoop, or post-tussive emesis without other apparent causes) among the out-patients between the ages of six and 14 years, Ghanaie RM et al. [4] reported that cough  $\geq 2$  weeks with whoop had a sensitivity of 71% and a specificity of 46%. We found that the sensitivity and specificity of MSS combined with a whoop among the out-patients were 73% vs. 64%, respectively (four months-9 years age group) and 71% vs. 74%, respectively ( $\geq 10$  years age group).

Our results showed that MSS combined with apnoea was a better predictor of pertussis among the in-patients than in the out-patients aged four months-9 years, possibly reflecting milder disease among the out-patients registered at primary health care centres.



Although the existing GPI case definition includes minimal fever or absence of fever depending on the age, many medical conditions can still resemble pertussis [12]. The differences in awareness and subjectivity of some signs and symptoms could influence the defined differences of sensitivity and specificity between the two surveillance systems and two studied age groups.

We recognize certain limitations of our investigations that should be addressed in future research.

Due to the limited number of participants, we could not perform a validation of certain symptoms in the 0–3 months age group. Further and more extensive prospective studies would be required to elucidate the GPI case definition for this age group.

For better evaluation of sensitivity and specificity, participants with non-infectious and infectious causes which are clinically similar to pertussis, should be excluded by applying rigorous laboratory tests for diagnosing alternative cough aetiologies.

## CONCLUSION

The findings of our study pointed out that multiple sign and symptom combinations of the GPI pertussis case definitions were good predictors for laboratory-confirmed pertussis. Since we have found that LR+ for many proposed signs and symptoms of the GPI case definitions was above 2, it is reasonable to consider the usefulness of these signs and symptoms to predict a diagnosis of pertussis. The addition of one or more signs and symptoms from the proposed case definition reduced the sensitivity but improved the specificity. Our study supported the fact that the choice of case definition in the recognition of pertussis should take into account the patient's age.

Further studies with larger samples to assess the validation of the GPI case definition for pertussis in other regions in various epidemiologic contexts are imperative.

## ACKNOWLEDGMENT

The authors thank Clemens Vlasich, Denis Macina, Philippe André, and Olga Lyabis for their support and valuable advices. The authors are grateful to all physicians who have participated in the surveillance of pertussis system in the City of Novi Sad, Vojvodina, Serbia during the 2013/2014 season.

## FUNDING

The study was partially funded by Sanofi Pasteur (Code: PER37-EXT). The funder played no role in the collection or analysis of data.

## NOTE

This study is a part of PhD thesis of Miodjub RISTIĆ.

**Conflict of interest:** Ulrich HEININGER is a member of the Global Pertussis Initiative (GPI) supported by an unrestricted grant from Sanofi Pasteur. The other authors declare no conflict of interest.

**REFERENCES**

1. World Health Organization, 2019. Immunization, vaccines and biologics. WHO-recommended surveillance standard of pertussis. World Health Organization, Geneva, Switzerland [accessed 2019 January 20]. Available from: [https://www.who.int/immunization/monitoring\\_surveillance/burden/vpd/surveillance\\_type/passive/pertussis\\_standards/en/](https://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/passive/pertussis_standards/en/)
2. Crespo I, Toledo D, Soldevila N, Jordán I, Solano R, Castilla J, et al. Characteristics of Hospitalized Cases of Pertussis in Catalonia and Navarra, Two Regions in the North of Spain. *PLoS One*. 2015; 10(10): e0139993. [DOI: 10.1371/journal.pone.0139993] [PMID: 26440655]
3. Edwards K, Decker MD. Whooping cough vaccine. In: Plotkin SA, Orenstein WA, Offit PA, editors. *Vaccines*. 6th ed. Philadelphia: Elsevier; 2013. Pp. 447–92.
4. Ghanaie RM, Karimi A, Sadeghi H, Esteghamti A, Falah F, Armin S, et al. Sensitivity and specificity of the World Health Organization pertussis clinical case definition. *Int J Infect Dis*. 2010;14(12): e1072–5. [DOI: 10.1016/j.ijid.2010.07.005] [PMID: 20951620]
5. Cherry JD, Grimprel E, Guiso N, Heininger U, Mertsola J. Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. *Pediatr Infect Dis J*. 2005; 24(5 Suppl):S25–34. [PMID: 15876920]
6. Koh MT, Liu CS, Chiu CH, Boonsawat W, Watanaveeradej V, Abdullah N, et al. Under-recognized pertussis in adults from Asian countries: a cross-sectional seroprevalence study in Malaysia, Taiwan and Thailand. *Epidemiol Infect*. 2016; 144(6):1192–200. [DOI: 10.1017/S0950268815002393] [PMID: 26468043]
7. Cherry JD, Tan T, Wirsing von König CH, Forsyth KD, Thisyakorn U, Greenberg D, et al. Clinical definitions of pertussis: Summary of a Global Pertussis Initiative roundtable meeting, February 2011. *Clin Infect Dis*. 2012; 54(12):1756–64. [DOI: 10.1093/cid/cis302] [PMID: 22431797]
8. Institute of Public Health of Vojvodina. [Communicable diseases in Vojvodina, 2015. Annual report]. Novi Sad: Institute of Public Health of Vojvodina; 2016. Pp. 112–16. (Serbian)
9. Petrović V, Šeguljev Z, Ristić M, Radosavljević B, Đilas M, Heininger U. Pertussis incidence rates in Novi Sad (Serbia) before and during improved surveillance. *Srp Arh Celok Lek*. 2017;145(3-4):165–72.
10. Patriarca PA, Biellik RJ, Sanden G, Burstyn DG, Mitchell PD, Silverman PR, et al. Sensitivity and specificity of clinical case definitions for pertussis. *Am J Public Health* 1988;78(7):833–6. [PMID: 3289409]
11. Nyawanda B, Mott JA, Njuguna HN, Mayieka L, Khagayi S, Onkoba R, et al. Evaluation of case definitions to detect respiratory syncytial virus infection in hospitalized children below 5 years in Rural Western Kenya, 2009–2013. *BMC Infect Dis*. 2016; 16:218. [DOI: 10.1186/s12879-016-1532-0] [PMID: 27207342]
12. Wessels MR, Brigham KS, DeMaria A Jr. Case records of the Massachusetts General Hospital. Case 6-2015. A 16-year-old boy with coughing spells. *N Engl J Med*. 2015; 372(8):765–73. [DOI: 10.1056/NEJMcp1411928] [PMID: 25693017]

**Table 1.** Signs and symptoms associated with laboratory confirmed pertussis infections in the sentinel and hospital surveillance of pertussis by age group

Age group with mandatory and other signs and symptoms of pertussis	Total (n = 319)	Positive (n = 103)	Negative (n = 216)	crude OR (95%CI)	p value	adjusted OR <sup>a, b</sup> (95%CI)	p value
<b>1) 0–3 months</b>							
Cough and coryza with no or minimal fever plus:	(n = 16) n (%)	(n = 5) n (%)	(n = 11) n (%)	Ref.			
Whoop	7 (43.8)	2 (40.0)	5 (45.5)	0.80 (0.09–6.85)	0.839	-	-
Apnoea	3 (18.8)	3 (60.0)	0 (-)	NA	ND	-	-
Post-tussive emesis	7 (43.8)	1 (20.0)	6 (54.5)	0.21 (0.02–2.52)	0.217	-	-
Cyanosis	5 (31.3)	1 (20.0)	4 (36.4)	0.44 (0.04–5.40)	0.519	-	-
Seizure	1 (6.3)	1 (20.0)	0 (-)	NA	ND	-	-
Pneumonia	5 (31.3)	3 (60.0)	2 (18.2)	6.75 (0.64–71.18)	0.112	-	-
Contact <sup>c</sup>	2 (12.5)	1 (20.0)	1 (9.1)	2.50 (0.12–50.45)	0.550	-	-
<b>2) 4 months–9 years</b>							
Paroxysmal cough with no or minimal fever plus:	(n = 124) n (%)	(n = 34) n (%)	(n = 90) n (%)	Ref.			
Whoop	55 (44.4)	23 (67.6)	32 (35.6)	3.79 (1.64–8.76)	<b>0.002</b>	3.63 (1.48–8.90)	<b>0.005</b>
Apnoea	13 (10.5)	9 (26.5)	4 (4.4)	7.74 (2.20–27.26)	<b>0.001</b>	10.11 (2.40–42.63)	<b>0.002</b>
Post-tussive emesis	52 (41.9)	21 (61.8)	31 (34.4)	3.07 (1.36–6.96)	<b>0.007</b>	3.51 (1.44–8.57)	<b>0.006</b>
Worsening of symptoms at night	58 (46.8)	21 (61.8)	37 (41.1)	2.31 (1.03–5.20)	<b>0.042</b>	3.29 (1.31–8.25)	<b>0.011</b>
Pneumonia	8 (6.5)	1 (2.9)	7 (7.8)	0.36 (0.04–3.04)	0.347	-	-
Seizure	0 (-)	0 (-)	0 (-)	NA	ND	NA	ND
Contact <sup>c</sup>	20 (16.1)	10 (29.4)	10 (11.1)	3.33 (1.24–8.95)	<b>0.017</b>	5.68 (1.76–18.35)	<b>0.004</b>
<b>3) ≥10 years</b>							
Nonproductive, paroxysmal cough of ≥2 weeks duration without fever plus:	(n = 179) n (%)	(n = 64) n (%)	(n = 115) n (%)	Ref.			
Whoop	76 (42.5)	44 (68.8)	32 (27.8)	5.71 (2.93–11.12)	<b>&lt;0.001</b>	4.64 (2.29–9.41)	<b>&lt;0.001</b>
Apnoea	17 (9.5)	14 (21.9)	3 (2.6)	10.45 (2.88–38.00)	<b>&lt;0.001</b>	10.68 (2.74–41.54)	<b>0.001</b>
Sweating episodes between paroxysms	79 (44.1)	24 (37.5)	55 (47.8)	0.65 (0.35–1.22)	0.184	-	-
Post-tussive emesis	51 (28.5)	28 (43.8)	23 (20.0)	3.11 (1.59–6.10)	<b>0.001</b>	2.73 (1.32–5.67)	<b>0.007</b>
Worsening of symptoms at night	105 (58.7)	47 (73.4)	58 (50.4)	2.72 (1.40–5.28)	<b>0.003</b>	3.66 (1.74–7.69)	<b>0.001</b>

Values that differ significantly between positive and negative pertussis cases are marked in bold;

NA – not applicable; ND – not determined;

<sup>a</sup>Adjusted for the following variables: Age, gender, duration of cough and vaccination status (fully vaccinated persons compared with unvaccinated, partly vaccinated, and persons with unknown vaccination status together) for characteristics with significance difference according to univariate analysis;

<sup>b</sup>Not calculable and omitted in logistic regression analyses in the 0–3 months age group;

<sup>c</sup>Close exposure to an adolescent or adult (usually a family member) with a prolonged afebrile cough illness

**Table 2.** Diagnostic accuracy of signs and symptoms and their combinations of proposed case definitions of patients aged 4 months – 9 years with suspected pertussis infection

Surveillance system	Mandatory signs and symptoms plus:	Sensitivity % (95 % CI)	Specificity % (95 % CI)	PPV % (95 % CI)	NPV % (95 % CI)	LR+ (95 % CI)	LR- (95 % CI)
Sentinel surveillance (out-patients)	Whoop	73.3 (44.9–92.1)	63.8 (50.1–76.0)	34.4 (18.6–53.2)	90.2 (76.9–97.2)	2.0 (1.3–3.2)	0.4 (0.2–0.9)
	Apnoea	6.7 (1.1–32.0) <sup>a</sup>	94.8 (85.6–98.9)	25.0 (4.1–79.7)	79.7 (68.3–88.4)	1.3 (0.1–11.5)	1.0 (0.9–1.1)
	Post-tussive emesis	60.0 (32.3–83.6)	77.6 (64.7–87.5) <sup>b</sup>	40.9 (20.8–63.6)	88.2 (76.1–95.5)	2.7 (1.4–5.0)	0.5 (0.3–0.9)
	Worsening of symptoms at night	66.7 (38.4–88.1)	55.2 (41.5–68.3)	27.8 (14.2–45.2)	86.5 (71.2–95.4)	1.5 (0.9–2.4)	0.6 (0.3–1.3)
	Pneumonia	0.0 (-)	91.4 (81.0–97.1)	NA	77.9 (66.2–87.1)	NA	1.1 (1.0–1.2)
	Contact <sup>c</sup>	40.0 (16.4–67.7)	89.7 (78.8–96.1)	50.0 (21.2–78.8)	85.3 (73.8–93.0)	3.9 (1.5–10.3)	0.7 (0.4–1.0)
	Whoop + apnoea	6.7 (1.1–32.0)	94.8 (85.6–98.9)	25.0 (4.1–79.7)	79.7 (68.3–88.4)	1.3 (0.1–11.5)	1.0 (0.9–1.1)
	Whoop + post-tussive emesis	46.7 (21.3–73.4)	93.1 (83.3–98.1)	63.6 (30.9–88.9)	87.1 (76.1–94.2)	6.8 (2.3–20.1)	0.6 (0.4–0.9)
	Whoop + worsening of symptoms at night	40.0 (16.4–67.7)	82.8 (70.6–91.4)	37.5 (15.3–64.5)	84.2 (72.1–92.5)	2.3 (1.0–5.4)	0.7 (0.5–1.1)
	Whoop + Contact <sup>c</sup>	33.3 (12.0–61.6)	96.6 (88.1–99.5)	71.4 (29.3–95.5)	84.9 (73.9–92.5)	9.7 (2.1–45.0)	0.7 (0.5–1.0)
	Post-tussive emesis + worsening of symptoms at night	53.3 (26.7–78.7)	89.7 (78.8–96.1)	57.1 (28.9–82.2)	88.1 (77.1–95.1)	5.2 (2.1–12.6)	0.5 (0.3–0.9)
	Post-tussive emesis + Contact <sup>c</sup>	20.0 (4.6–48.1)	100.0 (-) <sup>b</sup>	100.0 (-)	82.9 (72.0–90.8)	NA	0.8 (0.6–1.0)
	Worsening of symptoms at night + Contact <sup>c</sup>	20.0 (4.6–48.1)	96.6 (88.1–99.5)	60.0 (15.4–93.5)	82.4 (71.2–90.5)	5.8 (1.1–31.7)	0.8 (0.6–1.1)
	Whoop + post-tussive emesis + worsening of symptoms at night	40.0 (16.4–67.7)	96.6 (88.1–99.5)	75.0 (35.1–96.1)	86.2 (75.3–93.5)	11.6 (2.6–51.8)	0.6 (0.4–0.9)
	Whoop + post-tussive emesis + worsening of symptoms at night + Contact <sup>c</sup>	13.3 (2.1–40.5)	98.3 (90.7–99.7)	66.7 (11.6–94.5)	81.4 (70.3–89.7)	7.7 (0.6–79.7)	0.9 (0.7–1.1)
Hospital surveillance (in-patients)	Whoop	63.2 (38.4–83.7)	65.6 (46.8–81.4)	52.2 (30.6–73.2)	75.0 (55.1–89.3)	1.8 (1.0–3.3)	0.6 (0.3–1.1)
	Apnoea	42.1 (20.3–66.5) <sup>a</sup>	96.9 (83.7–99.5)	88.9 (51.7–98.2)	73.8 (57.9–86.1)	13.5 (1.8–99.6)	0.6 (0.4–0.9)
	Post-tussive emesis	63.2 (38.4–83.7)	43.8 (26.4–62.3) <sup>b</sup>	40.0 (22.7–59.4)	66.7 (43.0–85.4)	1.1 (0.7–1.8)	0.8 (0.4–1.7)
	Worsening of symptoms at night	57.9 (33.5–79.7)	65.6 (46.8–81.4)	50.0 (28.3–71.8)	72.4 (52.8–87.2)	1.7 (0.9–3.1)	0.6 (0.4–1.2)
	Pneumonia	5.3 (0.9–26.1)	93.8 (79.2–99.1)	33.3 (5.5–88.5)	62.5 (47.4–76.0)	0.8 (0.0–8.7)	1.0 (0.9–1.2)
	Contact <sup>c</sup>	21.1 (6.2–45.6)	87.5 (70.9–96.4)	50.0 (16.0–83.9)	65.1 (49.1–78.9)	1.7 (0.5–5.9)	0.9 (0.7–1.2)
	Whoop + apnoea	31.6 (12.7–56.5)	96.9 (83.7–99.5)	85.7 (42.2–97.6)	70.5 (54.8–83.2)	10.1 (1.3–77.7)	0.7 (0.5–1.0)
	Whoop + post-tussive emesis	36.8 (16.4–61.6)	81.3 (63.6–92.8)	53.9 (25.2–80.7)	68.4 (51.4–82.5)	2.0 (0.8–5.0)	0.8 (0.5–1.1)
	Whoop + worsening of symptoms at night	31.6 (12.7–56.5)	84.4 (67.2–94.7)	54.6 (23.5–83.1)	67.5 (50.9–81.4)	2.0 (0.7–5.7)	0.8 (0.6–1.1)
	Whoop + Contact <sup>c</sup>	10.5 (1.6–33.2)	93.8 (79.2–99.1)	50.0 (8.3–91.7)	63.8 (48.5–77.3)	1.7 (0.3–11.0)	1.0 (0.8–1.1)
	Post-tussive emesis + worsening of symptoms at night	36.8 (16.4–61.6)	78.1 (60.0–90.7)	50.0 (23.1–76.9)	67.6 (50.2–82.0)	1.7 (0.7–4.1)	0.8 (0.6–1.2)
	Post-tussive emesis + Contact <sup>c</sup>	21.1 (6.2–45.6)	90.6 (75.0–97.9) <sup>b</sup>	57.1 (18.8–89.6)	65.9 (50.1–79.5)	2.3 (0.6–9.0)	0.9 (0.7–1.1)
	Worsening of symptoms at night + Contact <sup>c</sup>	15.8 (3.6–39.6)	96.9 (83.7–99.5)	75.0 (20.3–95.9)	66.0 (50.7–79.1)	5.1 (0.6–45.2)	0.9 (0.7–1.0)
	Whoop + post-tussive emesis + worsening of symptoms at night	21.1 (6.2–45.6)	87.5 (71.0–96.4)	50.0 (16.0–84.0)	65.1 (49.1–79.0)	1.7 (0.5–6.0)	0.9 (0.7–1.2)
	Whoop + post-tussive emesis + worsening of symptoms at night + Contact <sup>c</sup>	10.5 (1.6–33.2)	100.0 (-)	100.0 (-)	65.3 (50.4–78.3)	NA	0.9 (0.8–1.0)

NA – not applicable; PPV – positive predictive value; NPV – negative predictive value; LR+ – positive likelihood ratio; LR- –negative likelihood ratio;

<sup>a</sup>Sensitivity significantly different between the two surveillance systems;

<sup>b</sup>Specificity significantly different between the two surveillance systems;

<sup>c</sup>Close exposure to an adolescent or adult (usually a family member) with a prolonged afebrile cough illness

**Table 3.** Diagnostic accuracy of signs and symptoms and their combinations of proposed case definitions of patients aged  $\geq 10$  with suspected pertussis infection

Surveillance system	Mandatory signs and symptoms plus:	Sensitivity % (95 % CI)	Specificity % (95 % CI)	PPV % (95 % CI)	NPV % (95 % CI)	LR+ (95 % CI)	LR- (95 % CI)
Sentinel surveillance (out-patients)	Whoop	71.0 (52.0–85.8)	74.0 (64.5–82.1)	44.9 (30.7–59.8)	89.5 (81.1–95.1)	2.7 (1.8–4.1)	0.4 (0.2–0.7)
	Apnoea	16.1 (5.5–33.7)	97.1 (91.8–99.4)	62.5 (24.7–91.0)	79.5 (71.5–86.2)	5.6 (1.4–22.1)	0.9 (0.7–1.0)
	Sweating episodes between paroxysms	35.5 (19.3–54.6)	51.9 (41.9–61.8)	18.0 (9.4–30.0)	73.0 (61.4–82.6)	0.7 (0.4–1.2)	1.2 (0.9–1.7)
	Post-tussive emesis	61.3 (42.2–78.1) <sup>a</sup>	81.7 (73.0–88.6)	50.0 (33.4–66.6)	87.6 (79.4–93.4)	3.4 (2.1–5.5)	0.5 (0.3–0.7)
	Worsening of symptoms at night	61.3 (42.2–78.1) <sup>a</sup>	51.0 (41.0–60.9)	27.1 (17.2–39.1)	81.5 (70.0–90.1)	1.3 (0.9–1.8)	0.8 (0.5–1.2)
	Whoop + apnoea	12.9 (3.7–29.9)	99.0 (94.7–99.8)	80.0 (28.8–96.7)	79.2 (71.2–85.8)	13.4 (1.6–115.7)	0.9 (0.8–1.0)
	Whoop + post-tussive emesis	38.7 (22.0–57.8)	97.1 (91.8–99.4) <sup>b</sup>	80.0 (51.9–95.4)	84.2 (76.4–90.2)	13.4 (4.0–44.6)	0.6 (0.5–0.8)
	Post-tussive emesis + worsening of symptoms at night	32.3 (16.7–51.4)	90.4 (83.0–95.3)	50.0 (27.2–72.8)	81.7 (73.5–88.3)	3.4 (1.5–7.3)	0.8 (0.6–1.0)
	Apnoea + post-tussive emesis	16.1 (5.5–33.7)	99.0 (94.7–99.8)	83.3 (36.1–97.2)	79.8 (71.9–86.4)	16.8 (2.0–138.3)	0.9 (0.7–1.0)
	Whoop + sweating episodes between paroxysms + worsening of symptoms at night	9.7 (2.0–25.8)	95.2 (89.1–98.4)	37.5 (8.5–75.5)	78.0 (69.7–84.8)	2.0 (0.5–8.0)	1.0 (0.8–1.1)
	Whoop + sweating episodes between paroxysms + post-tussive emesis	16.1 (5.5–33.7)	99.0 (94.7–99.8)	83.3 (36.1–97.2)	79.8 (71.9–86.4)	16.8 (2.0–138.3)	0.9 (0.7–1.0)
	Whoop + worsening of symptoms at night + post-tussive emesis	19.4 (7.5–37.5)	98.1 (93.2–99.7)	75.0 (35.1–96.1)	80.3 (72.3–86.8)	10.1 (2.1–47.4)	0.8 (0.7–1.0)
	Apnoea + sweating episodes between paroxysms + post-tussive emesis	3.2 (0.1–16.7)	99.0 (94.8–99.9)	50.0 (1.3–98.7)	77.4 (69.4–84.2)	3.4 (0.2–52.1)	1.0 (0.9–1.0)
	Hospital surveillance (in-patients)	Whoop	66.7 (48.2–82.0)	54.6 (23.5–83.1)	81.5 (61.9–93.6)	35.3 (14.3–61.7)	1.5 (0.7–2.9)
Apnoea		27.3 (13.3–45.5)	100.0 (-)	100.0 (-)	31.4 (16.9–49.3)	NA	0.7 (0.6–0.9)
Sweating episodes between paroxysms		39.4 (22.9–57.9)	54.6 (23.5–83.1)	72.2 (46.5–90.2)	23.1 (9.0–43.7)	0.9 (0.4–1.9)	1.1 (0.6–2.0)
Post-tussive emesis		27.3 (13.3–45.5) <sup>a</sup>	63.6 (30.9–88.9)	69.2 (38.6–90.7)	22.6 (9.6–41.1)	0.8 (0.3–2.0)	1.1 (0.7–1.9)
Worsening of symptoms at night		84.9 (68.1–94.8) <sup>a</sup>	36.4 (11.2–69.1)	80.0 (63.1–91.5)	44.4 (14.0–78.6)	1.3 (0.8–2.1)	0.4 (0.1–1.3)
Whoop + apnoea		21.2 (9.0–38.9)	100.0 (-)	100.0 (-)	29.7 (15.9–47.0)	NA	0.8 (0.7–0.9)
Whoop + post-tussive emesis		18.2 (7.0–35.5)	81.8 (48.2–97.2) <sup>b</sup>	75.0 (35.1–96.1)	25.0 (12.2–42.2)	1.0 (0.2–4.3)	1.0 (0.7–1.4)
Post-tussive emesis + worsening of symptoms at night		24.2 (11.1–42.3)	72.7 (39.1–93.7)	72.7 (39.1–93.7)	24.2 (11.1–42.3)	0.9 (0.3–2.8)	1.0 (0.7–1.6)
Apnoea + post-tussive emesis		6.1 (0.9–20.3)	100.0 (-)	100.0 (-)	26.2 (13.9–42.0)	NA	0.9 (0.9–1.0)
Whoop + sweating episodes between paroxysms + worsening of symptoms at night		21.2 (9.0–38.9)	90.9 (58.7–99.8)	87.5 (47.4–99.7)	27.8 (14.2–45.2)	2.3 (0.3–16.9)	0.9 (0.7–1.1)
Whoop + sweating episodes between paroxysms + post-tussive emesis		6.1 (0.9–20.3)	90.9 (58.7–98.5)	66.7 (11.6–94.5)	24.4 (12.4–40.3)	0.7 (0.1–6.7)	1.0 (0.8–1.3)
Whoop + worsening of symptoms at night + post-tussive emesis		18.2 (7.0–35.5)	90.9 (58.7–98.5)	85.7 (42.2–97.6)	27.0 (13.8–44.1)	2.0 (0.3–14.8)	0.9 (0.7–1.2)
Apnoea + sweating episodes between paroxysms + post-tussive emesis		0.0 (-)	100.0 (-)	NA	25.0 (13.2–40.3)	NA	NA

NA – not applicable; PPV – positive predictive value; NPV – negative predictive value; LR+ – positive likelihood ratio; LR- – negative likelihood ratio;

<sup>a</sup>Sensitivity significantly different between the two surveillance systems;

<sup>b</sup>Specificity significantly different between the two surveillance systems